Effects of switching from clopidogrel to prasugrel at the chronic phase after coronary stenting on antiplatelet action and vascular endothelial function: Switch-Pras study

Taiki Masuyama1 · Masashi Sakuma1 · Ryutaro Waku1 · Suguru Hirose1 · Keijiro Kitahara1 · Jin Naganuma1 · Hiroko Yazawa1 · Shigeru Toyoda1 · Shichiro Abe1 · Toshiaki Nakajima1 · Teruo Inoue1

Received: 7 July 2020 / Accepted: 9 October 2020 / Published online: 28 October 2020 © The Author(s) 2020

Abstract
Compared to clopidogrel, prasugrel has a lower incidence of ischemic events following percutaneous coronary intervention (PCI) because of an early reduction during the acute phase in P2Y12 reaction units (PRU). The objective of this study was to compare the antiplatelet effect and vascular endothelial function of both drugs during the chronic phase after PCI. Patients who had undergone PCI and were confirmed to have no restenosis by follow-up coronary angiography under dual anti-platelet therapy with clopidogrel (75 mg/day) and aspirin (100 mg/day) were randomized to either continue clopidogrel or switch to prasugrel (3.75 mg/day). At baseline, prior to randomization we determined the CYP2C19 genotype. At the baseline and 24 weeks after randomization, the P2Y12 reactivity unit (PRU) was measured using the VerifyNow™ P2Y12 assay. Endothelial function was evaluated by flow-mediated vasodilation (FMD) and reactive hyperemia peripheral arterial tonometry (RH-PAT), while and circulating CD34+/CD133+/CD45low progenitor cells were measured by flow cytometric analysis. Serum high-sensitivity C-reactive protein (hsCRP) level was also measured. The PRU was reduced significantly in the prasugrel group (\(P = 0.0008\)), especially in patients who were intermediate or poor metabolizers based on the CYP2C19 genotype (\(P < 0.0001\)). This reduction was not observed in the clopidogrel group. The number of CD34+/CD133+/CD45low cells increased in the clopidogrel group (\(P = 0.008\)), but not in the prasugrel group. The hsCRP, FMD and reactive hyperemia index measured by RH-PAT did not change in either group. Prasugrel is potentially better than clopidogrel for preventing thrombotic events, although clopidogrel may have an advantage over prasugrel in terms of preventing atherosclerotic events. Proper use of thienopyridine drugs based on the CYP2C19 genotype has promising clinical potential.

Keywords Prasugrel · Clopidogrel · Platelet reactivity · Endothelial progenitor cell · Coronary artery disease

Introduction
Thienopyridines, a class of selective irreversible inhibitors of the adenosine diphosphate receptor, P2Y12, have been used widely for their antiplatelet action [1]. Dual anti-platelet therapy using thienopyridines along with aspirin is the gold standard treatment in patients with the acute coronary syndrome (ACS) and/or patients undergoing percutaneous coronary intervention (PCI) to prevent coronary events such as recurrence of ACS and/or stent thrombosis. Of the different types of thienopyridines, clopidogrel was used most frequently to prevent coronary events until several years ago [2]. However, recently an alternative thienopyridine, prasugrel, has been developed which provides stronger platelet inhibition than clopidogrel [3]. Two recent Japanese trials, PRASFIT-ACS (PRASugrel compared with clopidogrel For Japanese patientS with ACS undergoing PCI) [4] and PRASFIT-Elective (PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI) [5], demonstrated that prasugrel tended to reduce mid-term (24 weeks) ischemic events in patients with ACS as well as stable coronary artery disease who underwent PCI to a greater extent than that observed with clopidogrel. Moreover, analysis of 1-year follow-up data from a post-marketing observational study, PRASFIT-Practice II (Prasugrel for Japanese Patients
with Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) [6], showed long-term effectiveness and safety of prasugrel at dosages approved in Japan for the treatment of coronary artery disease patients undergoing PCI. It is likely that prasugrel causes a greater reduction in platelet reactivity than clopidogrel, the action of which may be affected by genetic variants of the cytochrome P450 enzyme, CYP2C19. However, there is little information as to whether prasugrel has greater benefits than clopidogrel on longer-term outcomes after PCI.

In the drug-eluting stent (DES) era the majority of midterm ischemic events are stent thrombosis. Therefore, to improve long-term ischemic outcomes it is necessary to prevent not only late thrombosis but also late restenosis (late catch-up) [7], neoatherosclerosis [8] and impaired vascular healing [9] of the target lesion. It is also essential to prevent the atherosclerotic process in the entire coronary artery system beyond the target lesions [10]. It has been suggested that thienopyridines have direct pleiotropic anti-atherosclerotic effects independent of their anti-platelet action, including improvement of vascular endothelial function [11], an anti-inflammatory action [12] and reduction of oxidative stress [13].

The present study in patients with coronary artery disease, the Switch-Pras study, was designed to investigate whether switching from clopidogrel to prasugrel during the late phase after PCI had beneficial effects in terms of subsequent platelet reactivity, mobilization of endothelial progenitor cells (EPCs) and vascular endothelial function.

**Methods**

**Study design**

The study was a prospective randomized controlled design. The study enrolled 100 patients with coronary artery disease who had received dual anti-platelet therapy with proton pump inhibitor (20 mg/day esomeprazole) after a PCI (100 mg/day aspirin and 75 mg/day clopidogrel) and were confirmed to have no stenotic lesions in target vessels in follow-up coronary angiography carried out 12 months later. After follow-up coronary angiography, the patients were assigned randomly using a computer-based random number table to continue receiving clopidogrel (clopidogrel group; \( n = 50 \)) or switch to 3.75 mg/day prasugrel (prasugrel group; \( n = 49 \)). Both treatments were combined with 100 mg/day aspirin and 20 mg/day esomeprazole. The patients were then followed-up for 24 weeks (Fig. 1). At baseline and before randomization we collected data of demographic and clinical characteristics, carried out a genetic analysis of the CYP2C19 polymorphism and performed clinical tests to assess platelet reactivity, to estimate the number of circulating CD34+/CD133+/CD45low cells as an EPC lineage, to measure the level of high sensitivity C-reactive protein (hsCRP) as an inflammatory biomarker, and to assess vascular endothelial function. The study was approved by the Dokkyo Medical University Hospital review board and was conducted in
full compliance with the Declaration of Helsinki and Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of Health, Labor, and Welfare. The details of the study were registered with the University Hospital Medical Information Network clinical trial registry (No. UMIN 000027321).

**Genetic analysis**

The genetic analysis was performed using the QIAamp Blood Kit (Qiagen, Hilden, Germany) to isolate genomic DNA. Genotyping of CYP2C19 single-nucleotide polymorphisms (SNP; 681G > A and 636G > A) was performed using the Invader DNA assay method (Third Wave Technologies, Madison, WI, USA). The SNP genotype was translated into a star-allele genotype and the patients classified into 3 phenotypes: extensive metabolizer (EM; *1/*1), intermediate metabolizer (IM; *1/*2, *1/*3), and poor metabolizer (PM; *2/*2, *2/*3, *3/*3) [14].

**Platelet reactivity testing**

Platelet reactivity was assessed using the VerifyNow® assay kit (Accumetrics, San Diego, CA, USA) according to the manufacturer’s instructions. Blood samples were collected in buffered sodium citrate tubes 8–24 h after intake of the antiplatelet agents, primarily in the morning after an overnight fast and a rest period of at least 20–30 min. Careful antecubital venipuncture was performed by an experienced nurse or physician using a 21-gauge syringe. The VerifyNow® assay measures adenosine diphosphate-induced platelet function as an increase in light transmittance expressed as P2Y12 reaction units (PRU) [15].

**Measurement of circulating CD34+/CD133+/CD45low cells**

Circulating CD34+/CD133+/CD45low cells, including EPCs were measured by flow cytometry using minor modifications of a previously described method [16–18]. In brief, EDTA-treated peripheral blood was incubated with the test or control reagent. The reagent mixture consisted of nucleic acid dye (SY-III-8; Molecular Probe, Eugene, OR, USA), peridinin chlorophil protein (PerCP)-conjugated anti-CD45 (Becton Dickinson, San Jose, CA, USA), fluorescein isothiocyanate (FITC)-conjugated anti-CD34 (Becton Dickinson) and phycoerythrin (PE)-conjugated anti-CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany). Isotype controls were used as the negative controls based on the species and immunoglobulin (Ig) G control antibodies (IgG1 isotype control; Becton Dickinson). Flow cytometric analysis was then performed using a FACS Calibur laser flow cytometer (Becton Dickinson) according to the manufacturer’s instructions. Each measurement consisted of 10⁶ events of all white blood cells, which exceeded the threshold set for SY-III-8 fluorescence (nucleated cells). The absolute number of CD34+/CD133+/CD45low cells per mL was calculated based on the cells-to-the whole-blood cell count.

**Measurement of high sensitivity C-reactive protein**

The blood was centrifuged at 2000g for 10 min at room temperature and the serum samples were frozen and stored at −80 °C until analysis. The high sensitivity C-reactive protein (hsCRP) level was measured by particle-enhanced technology on the Behring BN II nephelometer (Dade Behring, Newark, DE, USA), using monoclonal anti-CRP antibodies and a calibrator that was traceable to WHO Reference Material [19].

**Vascular endothelial function testing**

Brachial artery flow-mediated dilation (FMD) and reactive hyperemia-peripheral arterial tonometry (RH-PAT) were used to assess vascular endothelial function. Both procedures were performed simultaneously in the morning, according to the method previously described by Tomiyama et al. [20]; fasting overnight and abstaining from alcohol, smoking, caffeine and antioxidant vitamins for at least 12 h before the measurements. The patients were asked to rest in the sitting position in a quiet, dark, air-conditioned room (22 to 25 °C) for 5 min. They were then requested to rest again for at least 15 min in the supine position in the same room before the FMD and RH-PAT procedures. The FMD measurements were performed using UNEXEF18G (UNEX, Co, Nagoya, Japan), an ultrasound instrument specialized for FMD measurement. The RH-PAT procedure was carried out using an EndoPAT-2000 (Itamar Medical Ltd., Caesarea, Israel) to calculate the reactive hyperemia index (RHI).

**Statistical analysis**

Normality for distribution of the continuous variables was assessed using the Shapiro–Wilkinson test. Values were expressed as the mean values ± standard deviation (SD) for parametric data and median values and interquartile ranges for non-parametric data. Intergroup comparisons were performed using unpaired t tests for parametric data and Mann–Whitney U tests for non-parametric data. Intragroup comparisons were carried out using paired t tests for parametric data and the Wilcoxon signed-rank test for non-parametric data. Inter-group comparisons of categorical variables were performed using the χ² test. P < 0.05 was considered statistically significant.
Results

Baseline characteristics

Of the 100 enrolled patients, one patient in the prasugrel group was withdrawn because of discontinuation of prasugrel, leaving 99 patients in the full analysis set (clopidogrel group n = 50, prasugrel group n = 49). Baseline data for demographic and clinical characteristics were comparable in the two groups, with the exception that the incidence of hypertension and use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and calcium channel blockers were higher in the clopidogrel group. Drug-eluting stents were used in 30 patients (60%) in the clopidogrel group and in 36 patients (73%) in the prasugrel group. The period from PCI to follow-up coronary angiography was 14 ± 10 and 17 ± 10 months in the clopidogrel group and in 36 patients (73%) in the prasugrel group. In 30 patients (60%) in the clopidogrel group and in 36 patients (73%) in the prasugrel group, the PRU value was reduced significantly at 24 weeks after randomization in the prasugrel group compared with baseline [64 (50–95) to 89 (56–132) cells/1 × 10⁶ WBCs, P = 0.008]. However, it did not change significantly in the prasugrel group [75 (53–98) to 77 (60–110) cells/1 × 10⁶ WBCs, P = 0.353]. The number of cells at baseline (P = 0.770) as well as at 24 weeks (P = 0.209) was similar in the two groups (Fig. 3a). The hsCRP level did not change significantly at 24 weeks in both the clopidogrel and prasugrel groups [0.063 (0.029–0.135) to 0.058 (0.022–0.130) mg/dL, P = 0.588; 0.040 (0.021–0.080) to 0.040 (0.023–0.104) mg/dL, P = 0.858, respectively] (Fig. 3b). The FMD value did not change significantly at 24 weeks in both the clopidogrel and prasugrel groups (4.28 ± 2.27 to 4.65 ± 2.54%, P = 0.160; 5.15 ± 2.55 to 4.77 ± 1.82%, P = 0.087, respectively) (Fig. 3c). The RHI value also did not change significantly in both the clopidogrel and prasugrel groups (2.01 ± 0.47 to 1.96 ± 0.57%, P = 0.639; 2.02 ± 0.50 to 2.09 ± 0.50%, P = 0.503, respectively) (Fig. 3d).

In the limited patients belong to the IM + PM arm, the number of circulating CD34+/CD133+/CD45low cells tended to increase at 24 weeks in the clopidogrel group, although there was no statistical significance, while it did not change in the prasugrel group. The hsCRP level, FMD and RHI did not change in both the clopidogrel and prasugrel groups (Table 2).

Discussion

The present study demonstrated that switching from a maintenance dose of clopidogrel to that of prasugrel even during the late phase after PCI (i.e., at 24 weeks) resulted in greater inhibition of platelet reactivity, demonstrated as a reduction in the PRU value. This advantageous effect of prasugrel over clopidogrel was especially evident in the IM + PM arm but was absent in the EM arm.

Because clopidogrel is a prodrug that is biotransformed into its active moiety by cytochrome P450 enzymes, particularly CYP2C19, genetic variants of this enzyme may interfere with metabolic activation and the extent of platelet inhibition during treatment. On the other hand, prasugrel is not affected by CYP2C19 variants, because CYP3A4 and CYP2B6 are the predominant activators of prasugrel [21]. Therefore, selection of treatment in the EM, IM, or PM patients can be based on the CYP2C19 genotype, with platelet reactivity less inhibited by clopidogrel than by prasugrel in IM and PM patients. In the PRASFIT-ACS study,
Table 1  Baseline characteristics

|                          | Clopidogrel group (n = 50) | Prasugrel group (n = 49) | P value |
|--------------------------|----------------------------|--------------------------|---------|
| Age (years)              | 68 ± 11                    | 67 ± 9                   | 0.624   |
| Male gender, n (%)       | 39 (78)                    | 42 (86)                  | 0.320   |
| Body mass index (kg/m²)  | 25 ± 4                     | 24 ± 3                   | 0.180   |
| Underlying disease, n (%)|                           |                          | 0.588   |
| Stable angina pectoris   | 17 (34)                    | 16 (33)                  |         |
| Old myocardial infarction| 33 (66)                    | 33 (67)                  |         |
| PCI                       |                            |                          |         |
| CAG                       |                            |                          |         |
| LDL                       |                            |                          |         |
| HDL                       |                            |                          |         |
| eGFR                      |                            |                          |         |
| BNP                       |                            |                          |         |
| hs-CRP                    |                            |                          |         |
| ACE                       |                            |                          |         |
| ARB                       |                            |                          |         |
| WBC                       |                            |                          |         |
| Hypertension              | 41 (82)                    | 30 (61)                  | 0.021   |
| Diabetes                  | 24 (48)                    | 19 (39)                  | 0.354   |
| Dyslipidemia              | 36 (72)                    | 35 (71)                  | 0.950   |
| Smoking                   | 35 (70)                    | 31 (63)                  | 0.907   |
| Systolic blood pressure (mmHg) | 127 ± 16           | 127 ± 14                 | 0.821   |
| Diastolic blood pressure (mmHg) | 72 ± 12              | 74 ± 10                   | 0.293   |
| Fasting blood glucose (mg/dL) | 110 ± 25            | 114 ± 26                  | 0.346   |
| Hemoglobin A1c (%)        | 6.3 ± 0.8                  | 6.2 ± 0.6                 | 0.532   |
| LDL-cholesterol (mg/dL)   | 81 ± 19                    | 86 ± 19                   | 0.221   |
| HDL-cholesterol (mg/dL)   | 51 ± 12                    | 53 ± 13                   | 0.413   |
| Triglyceride (mg/dL)      | 137 ± 86                   | 125 ± 57                  | 0.454   |
| Creatinine (mg/dL)        | 0.84 ± 0.28                | 0.82 ± 0.17               | 0.646   |
| cGFR (mL/min/1.73 m²)     | 72 ± 20                    | 72 ± 16                   | 0.896   |
| Uric acid (mg/dL)         | 5.4 ± 1.2                  | 5.4 ± 1.1                 | 0.725   |
| BNP (pg/mL)               | 38 ± 28                    | 35 ± 30                   | 0.572   |
| hsCRP (mg/dL)             | 0.063 (0.029–0.135)        | 0.040 (0.021–0.080)       | 0.810   |
| Statins                   | 48 (96)                    | 49 (100)                  | 0.157   |
| ACE inhibitors/ARBs       | 47 (94)                    | 37 (76)                  | 0.010   |
| Beta blockers             | 29 (58)                    | 24 (49)                  | 0.368   |
| Calcium channel blockers  | 27 (54)                    | 16 (33)                  | 0.368   |
| Insulin                   | 1 (2)                      | 4 (8)                    | 0.032   |
| CYP2C19 phenotype, n (%)  |                           |                          | 0.684   |
| Extensive metabolizer     | 20 (40)                    | 19 (39)                  |         |
| Intermediate metabolizer  | 20 (40)                    | 23 (47)                  |         |
| Poor metabolizer          | 10 (10)                    | 7 (14)                   |         |
| P2Y12 reaction unit       | 198 ± 65                   | 192 ± 56                 | 0.610   |
| CD34+/CD133+/CD45low cell (cell/1 × 10⁶ WBC) | 64 (48–98)           | 71 (46–96)               | 0.956   |
| Flow-mediated dilation (%)| 4.18 ± 2.27                | 5.03 ± 2.37              | 0.078   |
| Reactive hyperemia index  | 2.00 ± 0.47                | 2.02 ± 0.51              | 0.780   |

Data for CD34+/CD133+/CD45low cell are indicated as median value and interquartile range.

PCI, percutaneous coronary intervention; CAG, coronary angiography; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; hs-CRP, high-sensitive C reactive protein; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; WBC, white blood cell.
randomization to receive either clopidogrel or prasugrel was conducted immediately after PCI, with all the patients receiving the first loading dose and then the maintenance dose of each agent. Similar to the present study, the PRAS-FIT-ACS study [22] also compared the PRU value between both agents, with the data stratified into two arms (IM + PM and EM). This showed in the EM patients that prasugrel had a quicker onset of action compared with that of clopidogrel, with significantly lower PRU at 2–4 and 5–12 h after the loading dose. However, the PRU was similar in both groups from week 4 onwards. In contrast, in the IM + PM patients, the PRU was significantly lower in the prasugrel group than in the clopidogrel group throughout the study period, including 2–4 and 5–12 h after the loading dose. Like the present study, Nishi et al. [23] investigated the effect of platelet reactivity inhibition by switching from maintenance clopidogrel to prasugrel. However, unlike the present study, their study was designed as a single-arm study and not a randomized group comparison study, in which clopidogrel was switched to prasugrel and at day 14 prasugrel was switched back to clopidogrel without a washout period. The results showed that prasugrel caused stronger platelet inhibition than clopidogrel. Shimamatsu et al. [24] investigated the effect on PRU in patients with long-term (median duration: 1824 days) dual anti-platelet therapy (aspirin plus clopidogrel) after PCI when switching from clopidogrel to prasugrel. Twenty-three patients with PRU ≥ 208 at enrollment were randomly assigned into either continuing to receive clopidogrel or switching to prasugrel. The PRU for IM + PM group was significantly reduced in switching from clopidogrel to prasugrel. Moreover, prasugrel showed a significant reduction in PRU value even when combined with proton pump inhibitor, esomeplazol. The results of the present study provide strong support for the findings of these earlier investigations. We propose that switching from clopidogrel to prasugrel may be a therapeutic option even during the late phase after PCI, especially in patients at higher risk of stent thrombosis.

The present study also compared the effects of clopidogrel and prasugrel treatment on the mobilization of CD34+/CD133+/CD45low cells, inflammatory reaction determined by hsCRP and vascular endothelial function determined by FMD and RH-PAT. There is evidence that thienopyridine drugs have pleiotropic anti-atherosclerotic effects that include improving vascular endothelial function. A single loading dose of clopidogrel has been shown to increase FMD in patients with stable coronary artery disease [25], while a maintenance dose of prasugrel increased FMD in patients with ACS undergoing PCI to a greater extent than that observed with clopidogrel [26, 27]. Contrary to expectations, our study showed FMD and RHI values as well as hsCRP level did not change 24 weeks after randomization.
compared with baseline in both the clopidogrel and prasugrel groups. However, the number of circulating CD34+/CD133+/CD45low cells, which we used as the EPC lineage, increased significantly at 24 weeks in the clopidogrel group. However, the number of these cells did not change significantly in the prasugrel group. The number of cells at 24 weeks was compatible with the two groups.

**Table 2** Comparison of changes in circulating CD34+/CD133+/CD45low cells, serum level of high sensitivity C-reactive protein and vascular endothelial function parameters in the IM + PM arm patients

|               | Clopidogrel          | Prasugrel          |
|---------------|----------------------|-------------------|
| CD34+/CD133+/CD45low cell (cell/1 × 10⁶ WBCs) | 72 (50–91)          | 75 (54–117)       |
| hsCRP (mg/dL) | 0.070 (0.026–0.146)  | 0.038 (0.022–0.126)|
| FMD (%)       | 4.00 ± 2.27          | 5.16 ± 2.11       |
| RHI           | 2.00 ± 0.51          | 1.98 ± 0.49       |

IM intermediate metabolizer, IM poor metabolizer, WBCs white blood cells, hsCRP high sensitivity C-reactive protein, FMD flow-mediated dilation, RHI reactive hyperemia index

statistical significance. Our results suggest that clopidogrel might induce mobilization of EPCs, independently of platelet reactivity.

EPCs play a major role in the pathogenesis of atherosclerosis, with a decrease in the number of these cells indicating vascular endothelial injury and thereby acting as an independent predictor of morbidity and mortality of cardiovascular diseases. It is considered that the regulation
of the number and function of EPCs directly influences the maintenance and development of atherosclerosis [17, 28]. Therefore, it is clinically important to increase EPC bioactivity using appropriate interventions. It has been reported that clopidogrel enhances atorvastatin-induced mobilization of EPCs as demonstrated by the presence of CD34+/CD133+/KDR + cells in patients with coronary artery disease [29]. In a rabbit model of atherosclerosis produced by a combination of a high cholesterol diet and balloon catheter-injury of the iliac artery, clopidogrel induced endothelial regeneration that involved re-endothelialization and neointimal coverage over denuded luminal surfaces of the vessel to a greater degree than aspirin and equivalent to that caused by atorvastatin [30]. EPCs contribute to re-endothelialization of injured vessels and neovascularization of ischemic tissues. In the wound healing process after PCI using stent implantation, EPCs are mobilized at the acute phase, resulting in re-endothelialization of the denuded vessel surface and neointimal coverage over the stent struts at the long-term phase. Drug-eluting stents inhibit the EPC mobilization, leading to impaired vascular healing [9, 16, 18]. We previously observed impaired vascular healing 12 months after implantation of a drug-eluting stent using optical coherence tomography and coronary angiography [18]. In the present study, drug-eluting stents were used in more than 66% of the patients. Therefore, in perspective of vascular healing after stent implantation, clopidogrel would be advantageous over prasugrel, since the continuation of clopidogrel compared to a switch to prasugrel promoted a subsequent increase in CD34+/CD133+/CD45low cells in the present study. Since atherosclerosis is a chronically progressive disease, with reduced number and dysfunction of EPCs, clopidogrel might have a continuous potentiality to enhance the EPCs even after chronic phase after PCI.

Potential limitation

Although the present study was designed as a prospective, randomized, group comparison study, determination of the sample size required to provide sufficient statistical power was not performed. In addition, randomization was performed using a computer-based random number table without covariate adaptation and, therefore, inter-group comparisons of baseline characteristics showed significant differences for several variables. Because our study included a small number of patients we could not set cardiovascular events as an endpoint, but alternatively assessed surrogate endpoints such as platelet reactivity and vascular endothelial function. Larger scale, event-driven trials with stratified randomization to treatment are required to verify the validity of our results.

Clinical implication/conclusions

The duration of dual anti-platelet therapy with aspirin and thienopyridines has been widely debated since the beginning of the drug-eluting stent era. Previously long-term dual-antiplatelet therapy was required because of concerns regarding impairment of vascular healing after implantation of a drug-eluting stent and subsequent late or very late thrombosis. However, recently the duration of this therapy has become shorter with generational advances in the performance of drug-eluting stents. More recently, it has been recommended that thienopyridine, but not aspirin, should be administered as anti-platelet monotherapy following dual-anti-platelet therapy [31]. Although the present study was designed to investigate the effects of switching from clopidogrel to prasugrel for dual anti-platelet therapy during the late phase after PCI, we believe our results could be applied to long-term anti-platelet monotherapy. Our results suggest that prasugrel is potentially better than clopidogrel for preventing thrombotic events, especially in patients with IM or PM in the CYP2C19 genotype, but that clopidogrel may have some advantage over prasugrel for vascular healing after stent implantation. From our results, we envisage that proper use of any thienopyridine drug based on the CYP2C19 genotype would be clinically beneficial.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Alexopoulos D (2014) P2Y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. Cardioiology 127:211–219
2. Depta JP, Bhatt DL (2008) Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance. Am J Cardiovasc Drugs 8:91–112
1. Angiolillo DJ, Bates ER, Bass TA (2008) Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 156(2 Suppl):S16–S22
2. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M (2014) Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT–ACS study. Circ J 78:1684–1692
3. Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeka Y, Nakamura M, Saito S, PRASFIT-Elective Investigators (2014) Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 78:2926–2934
4. Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, Iizuka T (2019) Prasugrel for Japanese patients with ischemic heart disease in long-term clinical practice (PRASFIT-Practice II): 1-year follow-up results of a postmarketing observational study. Circ J 84:101–108
5. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW (2003) Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107:381–383
6. Nakazawa G, Otsuka F, Nakano M, Morooka T, Sakuma M, Node K, Simon DI (2018) Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome: a randomized, blinded, parallel group study. Atherosclerosis 296:689–695
7. Inoue T, Croce K, Morosoka T, Sakuma M, Node K, Simon DI (2011) Vascular inflammation and repair: implication for reendothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4:1057–1066
8. Kubo T, Imanishi T, Kashwagi H, Kuroi A, Ishibashi K, Komukai K, Tanimoto T, Ito Y, Kitabata H, Takarada S, Tanaka A, Mizukoshi M, Akasaka T (2010) Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol 105:318–322
9. Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Gori T (2014) Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers: a randomized crossover study. JACC Cardiovasc Interv 11:1576–1586
10. Thomas MR, Storey RF (2015) Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 114:490–497
11. An X, Jiang G, Cheng C, Lv Z, Liu Y, Wang F (2018) Inhibition of platelets by clopidogrel suppressed Ang II-induced vascular inflammation, oxidative stress, and remodeling. J Am Heart Assoc 7(21):e009600. https://doi.org/10.1161/JAHA.118.009600
12. Martis S, Peter I, Hulot J-S, Kornreich R, Desnick RJ, Scott SA (2013) Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 13:369–377
13. Price MJ (2009) Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119:2625–2632
14. Inoue T, Sata M, Hikichi Y, Soma R, Okuda D, Uchida T, Shimizu M, Komoda H, Node K (2007) Mobilization of CD34-positive bone marrow-derived stem cells after coronary stent implantation: impact on restenosis. Circulation 115:553–561
15. Arao K, Yusa T, Ohmura N, Tsukamoto Y, Murata M, Kubo N, Umemoto T, Ikeka N, Ako J, Ishikawa S, Kawakami M, Momomura S (2010) Circulating CD34+CD133+ progenitor cells in patients with stable angina pectoris undergoing percutaneous coronary interventions. Circ J 74:1929–1935
16. Sakuma M, Nasuno T, Abe S, Obi S, Toyoda S, Taguchi I, Sohma R, Inoue K, Nishino S, Node K, Attizzani G, Bezzera H, Costa M, Simon D, Inoue T (2018) Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography. Int J Cardiol Heart Vasc 18:17–24
17. Rifai N, Tracy RP, Ridker PM (1999) Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45:2136–2141
18. Tomiyama H, Yoshida M, Higashi Y, Takase B, Furumoto T, Kario K, Ohya Y, Yamashinab-subgroup study of FMD-J A (2014) Autonomic nervous activation triggered during induction of reactive hyperemia exerts a greater influence on the measured reactive hyperemia index by peripheral arterial tonometry than on flow-mediated vasodilatation of the brachial artery in patients with hypertension. Hypertens Res 37:914–918
19. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735–741
20. Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Ikeka Y, Nakamura M, Tanaka Y, Saito S (2016) Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: the PRASFIT–ACS study. J Cardiol 68:29–36
21. Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Takanbara M, Wakahayashi S, Hoshizaka M, Hanaoka H, Kobayashi Y (2015) Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease. Circ J 79:2439–2444
22. Shimamatsu J, Sasaki KI, Katsuki Y, Kawasato T, Murasato Y, Yajima H, Ito Y, Tashiro H, Harada A, Hikazawa Y, Ishizaki A, Ishimatsu K, Kukumoto Y, Kakuma T, Ueno T (2020) Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart Vessels 35:312–322
23. Warmholz A, Ostad MA, Velich N, Trautmann C, Schinzl R, Walter U, Munzel T (2008) A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 196:689–695
24. Rudolph TK, Fuchs A, Klinke A, Schlichting A, Friedrichs K, Brandt JT, Darstein C, Jakubowski JA, Salazar DE (2007) Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz917
25. Schnorbus B, Daiber A, Jurk K, Warnke S, Koenig J, Lackner KJ, Münzel T, Gori T (2020) Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz917
26. França CN, Pinheiro LF, Izar MC, Brunialti MK, Salomão R, Bianco HT, Kasmas SH, Barbosa SP, de Nucci G, Fonseca FA (2012) Endothelial progenitor cell mobilization and platelet...
microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 76:729–736
30. Li M, Yi Z, Ren H, Zhang Yu, Zhu X (2007) Effect of clopidogrel on inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 194:348–356
31. Cannon CP, CAPRIE Investigators (2002) Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 90(7):760–762

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.